Navigation Links
Oramed Pharmaceuticals to Present at the 8th National Life Science & Technology Week ILSI -BIOMED Conference, Israel 2009
Date:6/10/2009

JERUSALEM, June 10 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB) (http://www.oramed.com), a developer of oral delivery systems, announced that Oramed was chosen to present at the 8th National Life Science & Technology Week ILSI-BIOMED Conference, Israel 2009. The presentation will be given by Mr. Nadav Kidron, President and CEO of Oramed, on Tuesday, June 16th during the BioPharma Session at 12:30 p.m. (local time) at the David Intercontinental Hotel in Tel-Aviv, Israel.

"The selection of Oramed as one of the companies to present at the ILSI-Biomed is a great opportunity that allows us to present our company to the leading biomedical, health care and life science professionals from all over the world," said Nadav Kidron, Oramed CEO.

For more information about the upcoming ILSI Biomed conference, please visit http://www2.kenes.com/biomed/Pages/Home.aspx

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed is seeking to revolutionize the treatment of diabetes through its patented flagship product, an orally ingestible insulin capsule currently in phase 2 clinical trials. Established in 2006, Oramed's technology is based on over 25 years of research by top research scientists at Jerusalem's Hadassah Medical Center. The Company's corporate and R&D headquarters are based in Jerusalem.

For more information, please visit http://www.oramed.com

Forward-looking statements

Some of the statements contained in this press release are forward-looking statements which involve known and unknown risks, uncertainties and other fac
'/>"/>

SOURCE Oramed Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Oramed Pharmaceuticals Announces Launch of Phase 2B Clinical Trials in South Africa of its Oral Insulin Capsule
2. Oramed Pharmaceuticals to Present Oral Insulin Phase 2A Trial Results at the Upcoming Annual Meeting of the ADA (June 5-9, New Orleans, LA)
3. Oramed Pharmaceuticals Completes Proof of Concept Study of Insulin Suppository
4. Oramed Pharmaceuticals Chosen to Present Results of GLP-1 Analog Enteral Administration Study at the Diabetes Technology Societys Eighth Annual Meeting (November 13-15, 2008; Bethesda, Maryland)
5. Oramed Pharmaceuticals Launches Phase 1A Trials of its Insulin Suppository
6. /K I L L K I L L K I L L -- Oramed Pharmaceuticals Inc./
7. Oramed Pharmaceuticals Commences Phase 2A Trials of its Oral Insulin Capsule on Type 1 Diabetics
8. Oramed Pharmaceuticals Launches GLP1-Analog Program, Based on its Proprietary Drug Delivery Platform
9. Oramed Pharmaceuticals Chosen to Present Oral Insulin Trial Results at EASD Conference (September 7-11, Rome)
10. Oramed Pharmaceuticals Announces Successful Phase 2A Clinical Trial of its Oral Insulin Capsule
11. Oramed Pharmaceuticals to Hold Conference Call on August 6 to Present Results of Phase 2A Oral Insulin Capsule Clinical Trials

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...DIEGO,Nov.25/PRNewswire-FirstCall/--NuVasive,Inc.(...opingproductsforminimallydisruptivesurgicaltreatme...encecallonMonday,November30,2009,at5:30p.m.ET/2:30...lativetoreimbursementfortheCompany,sproductsandwil...tionandanswersession.Thedial-innumbersare1-877-407...
(Date:11/25/2009)...MINGHAM,Mass.andSYDNEY,Nov.25/PRNewswire-FirstCall...IN),aleadinginnovatorandprovideroflessinvasive,min...zingthetreatmentofadvancedheartfailure,todayannoun...the21stAnnualPiperJaffrayHealthCareConferenceat8:0...ingheldattheNewYorkPalaceHotel,December1-2. ,, ...
(Date:11/24/2009)...ISON,N.J.,Nov.24/PRNewswire-FirstCall/--QuestDiagn...oviderofdiagnostictesting,informationandservices,a...erJaffrayHealthcareConferenceinNewYorkCity.Thepres...30a.m.EasternTime. ,, Duringtheconference,theco...approximate3%,operatingincometoexceed18%ofrevenues...
Breaking Medicine Technology:NuVasive Announces Conference Call and Webcast Regarding Reimbursement 2NuVasive Announces Conference Call and Webcast Regarding Reimbursement 3Quest Diagnostics To Speak At The 21st Annual Piper Jaffray Healthcare Conference 2EnVivo Pharmaceuticals Announces Results and Successful Completion of EVP 6124 Phase Ib IIa Trial at the International Conference on Alzheimers Diseas 13042 1EnVivo Pharmaceuticals Announces Results and Successful Completion of EVP 6124 Phase Ib IIa Trial at the International Conference on Alzheimers Diseas 13042 2Rare Cells Linked to Pediatric Cancers 51764 1Rare Cells Linked to Pediatric Cancers 51764 2Stem Cell Decision Opens New Doors May Spur More Research 51762 1Stem Cell Decision Opens New Doors May Spur More Research 51762 2Stem Cell Decision Opens New Doors May Spur More Research 51762 3
...dy to Indicate that Early Use of Estrogen May be,C...re-USNewswire/ -- A new analysis,of Women,s Health...nal of Medicine, shows significant reduction in ca...ne therapy (HT) compared,with women taking a place...n estrogen therapy and coronary artery calcium,(CA...
...NDS, Texas--(BUSINESS WIRE)--Jun 21, 2007 - Opexa,...ed in the,development and commercialization of cel...a in an open-label Phase I/II,extension clinical t...n(TM), for multiple sclerosis (MS). In this one-ye...g remitting (RRMS),and secondary progressive (SPMS...
Other Medicine Technology:Arterial Plaque Significantly Reduced in Women Age 50-59 Taking,Hormones, Says New Analysis of Women's Health Initiative Data 2Arterial Plaque Significantly Reduced in Women Age 50-59 Taking,Hormones, Says New Analysis of Women's Health Initiative Data 3Opexa Therapeutics Reports Positive Top-line Data in Phase I/II,Extension Trial with Tovaxin for Multiple Sclerosis 2Opexa Therapeutics Reports Positive Top-line Data in Phase I/II,Extension Trial with Tovaxin for Multiple Sclerosis 3Opexa Therapeutics Reports Positive Top-line Data in Phase I/II,Extension Trial with Tovaxin for Multiple Sclerosis 4Opexa Therapeutics Reports Positive Top-line Data in Phase I/II,Extension Trial with Tovaxin for Multiple Sclerosis 5
(Date:11/25/2009)...--DanielTouizer,CEOof Ci n e r gyHealth ,ana...nefitprograms,isconcernedthatthelabordepartment,sr...ansarewithoutafull-timejobandunlikelytohavehealthi...dbytheU-6number,whichhasspikedto17.5%,thehighestra...esestatisticsarealarmingasitmeansthatmanyAmericans...
(Date:11/25/2009)... Kaplan, MD, FACP, a former Board Chair and one of...e Los Angeles Biomedical Research Institute at Har...ed by the American College of Physicians for his l...ts April 22, 2010 meeting in Toronto, the American...h the Ralph O. Claypoole Sr. Memorial Award for De...
(Date:11/25/2009)...or patients with liver lesions, researchers find ,...- Adding the drug cetuximab to neoadjuvant chemoth...essful surgery in colorectal cancer patients with ...suggests. , , Tumors spread to other parts of ...ctal cancer. Most commonly, the cancer spreads to ...
(Date:11/25/2009)...-FirstCall/-- TheProvidenceServiceCorporation(Nas...ary,thenation,slargestcoordinatorofnon-emergencytr...fromtheStateofFloridaCommissionfortheTransportatio...ortationservicestobothMiami-DadeandVolusiaCounties...rtheinitial18monthterm,issubjecttofinalizedcontrac...
(Date:11/25/2009)...e-FirstCall/--ErnestB.Remo,Chairman/CEOof American...nnouncedtodaythatitsnewwebsitewentlive.Itincludesa...lyaccesstimelyinformationandsignuptoreceiveemailne...mericandiversifiedholdings.com ,, "Shareholder...providerelevantinformationtoshareholdersinmuchgrea...
Breaking Medicine News(10 mins):Health News:Cinergy Health Commentary on Health Care for the Unemployed 2Health News:1 of LA BioMed's founders to be honored 2Health News:Cetuximab Helps Treat Colorectal Cancer 2Health News:Providence Service Corporation's LogistiCare Subsidiary Announces Non-Emergency Medical Transportation Contracts Worth Over $11 Million Annually in Florida 2Health News:Providence Service Corporation's LogistiCare Subsidiary Announces Non-Emergency Medical Transportation Contracts Worth Over $11 Million Annually in Florida 3Health News:American Diversified Holdings Corporation Announces New Website 2
...entists have been so successful in winning these a...rch being performed at Scripps Florida and in the ..., Ph.D., chairman of the department, which is loca...rkable." , The grants, from the NIH and the Depar...
...09 In a new study, published in the May issue of ....com/locate/yexnr ), scientists at the University ...monly used to treat ulcers have significant neurop... that proton pump inhibitors are also antiinflamma...
...2 April 2009 - Olivier Voinnet from the CNRS Insti...nce, is awarded the 2009 EMBO Gold Medal. The rese... on the mechanisms and roles of gene silencing via...chers in the molecular life sciences. The EMBO Gol...
...he YWCA USA will join many of its local affiliated...CA Day on April 24. This year,s theme is "Women Cr...ll advocate for an end to violence against women a... reaffirms our common commitment to world peace...
...st Widely Used PHR, Offers Convenience and Health ...aiser Permanente announced today that more than 3 ... personal health record available on www.kp.org ....zation,s personal health record an effective, easy...
...2 In celebration of Earth Day 2009, Sensitech Inc...tions, introduces a "Green Solutions" Recycling Pr...e data collection instruments for recycling. Sensi.../cgi-bin/prnh/20050209/NEW018LOGO ) , , For ma...
Other Medicine News:Health News:Scripps Research cancer biology department awarded more than $8 million in new research grants 2Health News:Commonly used ulcer drugs may offer treatment potential in Alzheimer's disease 2Health News:Olivier Voinnet awarded 2009 EMBO Gold Medal 2Health News:Olivier Voinnet awarded 2009 EMBO Gold Medal 3Health News:Three Million People Now Using Kaiser Permanente's Personal Health Record 2Health News:Three Million People Now Using Kaiser Permanente's Personal Health Record 3Health News:Sensitech Announces 'Green Solutions' Recycling Program 2Health News:Sensitech Announces 'Green Solutions' Recycling Program 3
Richardson Retractor
Smooth Round Moderate Plus Profile Breast Implant
Advanta™ ePTFE facial implants
Chin Implants
Medicine Products: